These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. Pozzilli P Nat Rev Endocrinol; 2011 Dec; 8(2):78-80. PubMed ID: 22183128 [TBL] [Abstract][Full Text] [Related]
46. Novel therapies for T1D on the horizon. Ben Nasr M; Fiorina P Pharmacol Res; 2015 Aug; 98():1-2. PubMed ID: 25882249 [No Abstract] [Full Text] [Related]
47. Editorial - Moving forward on the pathway of targeted immunotherapies for type 1 diabetes: the importance of disease heterogeneity. Infante M; Ricordi C Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8702-8704. PubMed ID: 31646605 [No Abstract] [Full Text] [Related]
48. Immunotherapy of type I diabetes: rationale, results and prospects. Pozza G; Pastore MR; Bosi E Pharmacol Res; 1992 Sep; 26 Suppl 2():110-1. PubMed ID: 1409267 [No Abstract] [Full Text] [Related]
49. Immunotherapy of immune-mediated diabetes. Present and future. Maclaren N Clin Rev Allergy Immunol; 2000 Dec; 19(3):277-97. PubMed ID: 11138410 [No Abstract] [Full Text] [Related]
50. The SAgA of Antigen-Specific Immunotherapy for Type 1 Diabetes. Mallone R; You S Diabetes; 2021 Jun; 70(6):1247-1249. PubMed ID: 34016601 [No Abstract] [Full Text] [Related]
51. Immunosuppression and type I diabetes. Dupre J; Stiller CR; Gent M Lancet; 1987 Mar; 1(8533):634. PubMed ID: 2881173 [No Abstract] [Full Text] [Related]
52. Immune intervention yes, but for what reason, for whom, when and how? Lernmark A Diabetologia; 1992 Nov; 35(11):1096-8. PubMed ID: 1473622 [No Abstract] [Full Text] [Related]
53. A machine learning approach to predict response to immunotherapy in type 1 diabetes. Fousteri G; Rodrigues EM; Giamporcaro GM; Falcone M Cell Mol Immunol; 2021 Mar; 18(3):515-517. PubMed ID: 33318626 [No Abstract] [Full Text] [Related]
54. [Diabetes by immunotherapy]. Manzano N; Ocampo P; Nicolini C; Halac S; Aguirre M; Rivero S; Zylberman M Medicina (B Aires); 2018; 78(1):60. PubMed ID: 29360082 [No Abstract] [Full Text] [Related]
55. Company man. Dancer James Samson manages type 1 diabetes on and off stage. Neithercott T Diabetes Forecast; 2014 Sep; 67(9):42-7. PubMed ID: 25211833 [No Abstract] [Full Text] [Related]
56. Statement on Unproven Therapies for Type 1 Diabetes. Pediatr Diabetes; 2018 Nov; 19(7):1337. PubMed ID: 30295418 [No Abstract] [Full Text] [Related]
57. Immunotherapy in type I diabetes. Postgrad Med; 1987 May; 81(6):159-60. PubMed ID: 27237991 [No Abstract] [Full Text] [Related]
58. [Immunointervention in type 1 diabetes mellitus]. Vialettes B Diabete Metab; 1992; 18(1):3-10; discussion 11-3. PubMed ID: 1563533 [No Abstract] [Full Text] [Related]
59. Outlook for immune intervention in type I diabetes. Grob PJ Curr Probl Clin Biochem; 1983; 12():119-40. PubMed ID: 6360542 [No Abstract] [Full Text] [Related]
60. Immune intervention in type I diabetes mellitus--current clinical and experimental approaches. Kolb H Exp Clin Endocrinol; 1994; 102(4):269-72. PubMed ID: 7813597 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]